No article text was recorded for this version.
external validity gap
Version 1 of 139 papers45 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Double-Blind Randomized Placebo-Controlled Trials in the Treatment of Affective Disorders: Problems and Alternatives
- Blog: Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations
- Blog: From trial data to personalized medicine: a validated framework with an application to Crohn's disease
- Blog: Estimating population average treatment effects from experiments with noncompliance
- Blog: Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease
- Blog: Causal effect on a target population: A sensitivity analysis to handle missing covariates
- Blog: Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data
- Blog: Doubly robust estimators for generalizing treatment effects on survival outcomes from randomized controlled trials to a target population
- Blog: Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
- Blog: Comparing and Contrasting A Priori and A Posteriori Generalizability Assessment of Clinical Trials on Type 2 Diabetes Mellitus
- Blog: Primary and Secondary Prevention of Ischemic Stroke in Elderly Patients with Cardiovascular Disease: The Role of Frailty and Care Pathways
- Blog: Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity
- Blog: Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia
- Blog: Correction: Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects
- Blog: An Empathetic AI Coach for Self-Attachment Therapy
- Blog: A practical analysis procedure on generalizing comparative effectiveness in the randomized clinical trial to the real-world trial-eligible population
- Blog: Generating high-fidelity privacy-conscious synthetic patient data for causal effect estimation with multiple treatments
- Blog: Exposure Therapy With Personalized Real-Time Arousal Detection and Feedback to Alleviate Social Anxiety Symptoms in an Analogue Adult Sample: Pilot Proof-of-Concept Randomized Controlled Trial
- Blog: A Unified Framework for the Transportability of Population-Level Causal Measures
- Blog: Electronic Medical Records Assisted Digital Clinical Trial Design
- Blog: Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
- Blog: Multimodal child-robot interaction: building social bonds
- Blog: Clinical outcomes of pharmacological therapies for heart failure in Black vs. White populations: a meta-analysis of randomized controlled trials of heart failure treatment
- Blog: Advancing Clinical Trials via Real-World Aligned ML Best Practices
- Blog: Designing Transportable Experiments Under S-admissability
- Blog: Design and Assessment of Representative Hybrid Clinical Trials using Health Recommender System
- Blog: Real World Evidence (RWE) in der Phytotherapie
- Blog: A Distribution-based Method for Assessing The Differences between Clinical Trial Target Populations and Patient Populations in Electronic Health Records
- Blog: Whose Personae? Synthetic Persona Experiments in LLM Research and Pathways to Transparency
- Blog: Sharp Bounds for Treatment Effect Generalization under Outcome Distribution Shift
- Blog: Advanced Robotic Therapy Integrated Centers (ARTIC): an international collaboration facilitating the application of rehabilitation technologies
- Blog: Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012
- Blog: How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov
- Blog: Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details
- Blog: Externally Valid Policy Evaluation from Randomized Trials Using Additional Observational Data
- Blog: <i>Who Are We Missing?</i> : A Principled Approach to Characterizing the Underrepresented Population
- Blog: Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study
- Blog: Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects
- Blog: Transforming Psychiatry into Data-Driven Medicine with Digital Measurement Tools
History & citation
Current · Permanent link
- This direction split from Generalizing Randomized Controlled Trials to Real-World Populations (54% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_external_validity_gap_173fab56,
title = {external validity gap},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/external-validity-gap/rdr_173fab56761746a1b6fd4b5d0534a135},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 1, frozen text):
@misc{lacuna_external_validity_gap_173fab56_v1,
title = {external validity gap},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/external-validity-gap/rdr_173fab56761746a1b6fd4b5d0534a135/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}